The ETV6-NTRK3 gene fusion is an oncogenic driver found in various cancers, including infantile fibrosarcoma, secretory breast cancer, and some leukemias. This fusion results in constitutive activation of the NTRK3 kinase domain, promoting uncontrolled cell proliferation and survival. While TRK inhibitors (e.g., larotrectinib, entrectinib) have shown remarkable efficacy, resistance often develops. CRISPR-Cas9 gene editing offers a revolutionary approach to directly target the ETV6-NTRK3 fusion, providing new avenues for research and therapy.
ETV6 (ETS variant 6) is a transcription factor, while NTRK3 (Neurotrophic Receptor Tyrosine Kinase 3) regulates neuronal growth.
The fusion results from a chromosomal translocation (t(12;15)(p13;q25)), linking ETV6’s dimerization domain to NTRK3’s kinase domain.
This leads to:
Ligand-independent dimerization → Persistent kinase activation.
Downstream signaling via MAPK, PI3K/AKT, and PLCγ pathways → Tumor growth and survival.
Infantile fibrosarcoma (most common, ~90% harbor this fusion).
Secretory breast carcinoma (~90% prevalence).
Acute myeloid leukemia (AML) and congenital mesoblastic nephroma (rare cases).
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) guides the Cas9 nuclease to a specific DNA sequence.
Induces double-strand breaks (DSBs), allowing:
Gene knockout (disrupting the fusion oncogene).
Gene correction (repairing the translocation).
Epigenetic modulation (silencing the fusion without DNA cutting).
CRISPR can be designed to target:
The fusion junction, preventing expression of the oncogenic protein.
The NTRK3 kinase domain, abolishing its activity.
Introducing the fusion into cell lines or organoids to study:
Tumorigenesis mechanisms.
Drug resistance pathways.
Larotrectinib resistance often arises from NTRK3 kinase domain mutations (e.g., G623R).
CRISPR can:
Edit resistant mutations to restore drug sensitivity.
Knock out alternative survival pathways (e.g., PI3K/AKT).
Ex vivo therapy: Editing patient-derived T cells or hematopoietic stem cells (HSCs) to eliminate fusion-positive clones.
In vivo delivery: Using lipid nanoparticles (LNPs) or AAV vectors to deliver CRISPR to tumors.
CRISPR + TRK inhibitors:
Disrupting the fusion while using larotrectinib to block residual activity.
CRISPR + immunotherapy:
Enhancing CAR-T cell therapy by knocking out immune checkpoints (e.g., PD-1) in ETV6-NTRK3-targeted T cells.
More precise than standard CRISPR, allowing:
Correction of the translocation in early-stage cancers.
Silencing the fusion promoter without DNA breaks.
Delivery Efficiency
Improving viral (AAV) and non-viral (LNPs) delivery to tumor sites.
Off-Target Effects
Using high-fidelity Cas9 variants (e.g., HiFi-Cas9) to minimize unintended edits.
Resistance Mechanisms
Tumors may develop alternative fusions (e.g., EML4-NTRK3); multi-target CRISPR strategies needed.
Clinical Translation
Ongoing preclinical studies; first-in-human trials pending.
The ETV6-NTRK3 fusion is a high-value target in precision oncology, and CRISPR-Cas9 offers a transformative approach to disrupt, correct, or silence this oncogene. While challenges remain in delivery and specificity, combining CRISPR with TRK inhibitors or immunotherapy could overcome resistance and improve outcomes for patients with ETV6-NTRK3-driven cancers. Future advancements in base editing and in vivo delivery will be critical for clinical success.
